Pfizer (PFE) Other Non-Current Liabilities (2009 - 2026)

Pfizer has disclosed Other Non-Current Liabilities across 18 years of filings, most recently posting $3.7 billion for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 35.27% year-over-year to $3.7 billion; the TTM figure through Mar 2026 stood at $3.7 billion (down 35.27% YoY), while the FY2025 annual figure was $3.6 billion, down 41.25% from the prior year.
• Other Non-Current Liabilities rose to $3.7 billion in Q1 2026, from $3.6 billion in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for PFE reached as high as $16.1 billion in Q2 2024 and fell as low as $3.6 billion in Q4 2025.
• The 5-year median for Other Non-Current Liabilities is $8.6 billion (2024), against an average of $9.4 billion.
• The widest YoY moves for Other Non-Current Liabilities: up 130.4% in 2025, down 41.25% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $13.2 billion in 2022, then plunged by 35.25% to $8.5 billion in 2023, then fell by 28.38% to $6.1 billion in 2024, then sank by 41.25% to $3.6 billion in 2025, then increased by 3.17% to $3.7 billion in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $3.7 billion, $3.6 billion, and $13.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.